Since PTPH1 is overexpressed in about 50% primary breast cancer [20], further investigation are warranted to determine if patients with PTPH1-overexpressed breast cancer will respond better to combination therapies of TKIs with anti-estrogens. The gene discussed is PTPN3; the disease is breast carcinoma.